

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K
CURRENT REPORT

Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 17, 2019

RUBICON TECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation)	001-33834 (Commission File Number)	36-4419301 (I.R.S. Employer Identification No.)
---	--	---

900 East Green Street Bensenville, Illinois (Address of principal executive offices)	60106 (Zip Code)
--	---------------------

(847) 295-7000
(Registrant's telephone number, including area code)

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered

Item 7.01 Regulation FD Disclosure.

On May 23, 2019, the Company issued a press release announcing the Launch of Direct Dose Rx. A copy of the press release is attached hereto as Exhibit 99.1.

The above information (including Exhibit 99.1) is furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, except as may be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

The following exhibits are filed or furnished as part of this report:

Exhibit No.	Description
99.1**	Press release dated May 23, 2019.

** Furnished herewith.

RUBICON TECHNOLOGY, INC.

Dated: May 23, 2019

By: /s/ Timothy E. Brog

Name: Timothy E. Brog

Title: Chief Executive Officer, President and Interim Chief
Financial Officer

2

EXHIBIT INDEX

Exhibit No.	Description
99.1**	Press release dated May 23, 2019.

** Furnished herewith.

3

EX-99.1 2 f8k051719ex99-1_rubicontech.htm PRESS RELEASE DATED MAY 23, 2019.

Exhibit 99.1

RUBICON TECHNOLOGY LAUNCHES DIRECT DOSE RX – A DIRECT TO PATIENT PHARMACY SOLUTION

Stamford, Connecticut – May 23, 2019 – Rubicon Technology, Inc. (Nasdaq: RBCN) announced today it has acquired certain equipment and assets from a large Indiana based pharmacy operation, including its licenses to operate in 11 states. In addition to the acquired assets, Rubicon hired their highly skilled employees and was able to maintain the necessary licenses to continue to operate the pharmacy operations. Rubicon DTP LLC, a newly formed wholly owned subsidiary of Rubicon Technology, will primarily operate this business under the name Direct Dose Rx.

Direct Dose Rx is focused on the delivery of prescription medication, over-the-counter drugs and vitamins to skilled nursing facilities and hospitals for patients that are being discharged. Direct Dose Rx also intends to service retail customers who have monthly needs for multiple prescriptions, over-the-counter drugs and vitamins and who wants such medications delivered to their home. The delivered products are sorted by the dose, date and time to be taken and come in an easy to use perforated strip-packaging as opposed to separate pill bottles.

The services offered by Direct Dose Rx benefits patients, skilled nursing facilities and hospitals by dramatically reducing the risk of hospital readmissions.

“I am looking forward to working with the team at Direct Dose Rx to build a world class pharmacy operation that utilizes a transformative approach to medication delivery,” said Timothy Brog, the Chief Executive Officer of Rubicon Technology. “Although this type of transaction was not exactly what Rubicon was looking for, the low risk and high rewards of this investment are compelling.”

Any Rubicon Technology shareholder who orders from Direct Dose Rx, or refers it a viable customer, will receive for the initial order a \$25 gift card to be used at Amazon, Walgreens or CVS.

About Rubicon Technology, Inc.

Rubicon Technology, Inc. owns Rubicon DTP LLC and Rubicon Technology Worldwide LLC. Rubicon Technology is also exploring various other alternatives to enhance stockholder value, including the acquisition of an existing business, establishing a new venture, or other investment opportunities in order to utilize its substantial net operating losses.

Rubicon Technology Worldwide LLC is an advanced materials provider specializing in monocrystalline sapphire products for optical systems and specialty electronic devices. Rubicon has a proprietary technology platform and expertise extending from the preparation of raw aluminum oxide through sapphire crystal growth and fabrication, enabling Rubicon to supply custom sapphire products with superior quality and precision. Rubicon is ISO 9001 certified and ITAR registered.

Forward-Looking Statements

Some statements included in this news release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and, therefore, involve uncertainties or risks that could cause actual results to differ materially therefrom. These statements may contain words such as "desires," "believes," "anticipates," "plans," "expects," "intends," "estimates," "seeks," "explores" or similar expressions. These statements are not guarantees of the Company's future performance and are subject to risks, uncertainties and other important factors that could cause actual performance or achievements to differ materially from those expressed or implied by these forward-looking statements. Such statements include, the pursuit or completion of any acquisition, sale, venture transaction or investment opportunity, or the Company's ability to maximize the value of its sapphire business, real estate or excess assets, utilize its net operating losses or to enhance stockholder value. Additional information regarding factors that could cause results to differ materially from management's expectations is found in the section entitled "Risk Factors" in the Company's 2018 Annual Report on Form 10-K filed with the SEC on March 22, 2019. The Company intends that the forward-looking statements included herein be subject to the above-mentioned statutory safe harbors. Investors are cautioned not to rely on forward-looking statements. The Company disclaims any obligation to update forward-looking statements.

Contact:

Rubicon Technology, Inc.
Timothy E. Brog
Chief Executive Officer
(847) 295-7000